A group of new life sciences start-ups have joined the tech community at Level39 in One Canada Square, E14.
The 80,000 sq ft specialist hub, which was launched by Canary Wharf Group 10 years ago, occupies the 39th, 26th and 24th floor of One Canada Square.
It is now home to over 180 start-ups and scaleups in the fintech, cyber security, cleantech, blockchain, life sciences and healthtech sectors.
New occupiers include TC BioPharm, a clinical stage biotechnology company; NeuralRays AI, an AI company; and Sanius Health, a health tech company dedicated to improving rare diseases treatment.
The Cancer Awareness Trust will also be moving into Level39 and has been joined by L-Base, a biotech company specialising in research and development of cancer drugs.
Congenica, a digital health company, has extended its long-term commitment to Level39 after becoming the exclusive provider of clinical decision support to Genomics England, which has also recently moved to One Canada Square.
The wider Canary Wharf cluster is set for the launch of the new life sciences innovation centre at 20 Water Street in June, followed by the delivery of a new 823,000 sq ft commercial laboratory building at North Quay in 2026, in partnership with Kadans Science Partner.
Kadans managing director James Sheppard said: “The rapid emergence of a community of life sciences companies at Level39 is a sure sign of the growing recognition of Canary Wharf’s potential as the home for a UK and European ecosystem of life sciences.”
See more lettings information in London, E14>>
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
